JP2016512216A5 - - Google Patents

Download PDF

Info

Publication number
JP2016512216A5
JP2016512216A5 JP2015562236A JP2015562236A JP2016512216A5 JP 2016512216 A5 JP2016512216 A5 JP 2016512216A5 JP 2015562236 A JP2015562236 A JP 2015562236A JP 2015562236 A JP2015562236 A JP 2015562236A JP 2016512216 A5 JP2016512216 A5 JP 2016512216A5
Authority
JP
Japan
Prior art keywords
composition
antibody
antigen
monoclonal antibody
main peak
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015562236A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512216A (ja
Filing date
Publication date
Priority claimed from FR1352360A external-priority patent/FR3003171B1/fr
Application filed filed Critical
Publication of JP2016512216A publication Critical patent/JP2016512216A/ja
Publication of JP2016512216A5 publication Critical patent/JP2016512216A5/ja
Pending legal-status Critical Current

Links

JP2015562236A 2013-03-15 2014-03-14 主要電荷アイソフォームに富んだ抗体組成物を含む新規な薬剤 Pending JP2016512216A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1352360 2013-03-15
FR1352360A FR3003171B1 (fr) 2013-03-15 2013-03-15 Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
PCT/EP2014/055179 WO2014140322A1 (fr) 2013-03-15 2014-03-14 Nouveaux médicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire

Publications (2)

Publication Number Publication Date
JP2016512216A JP2016512216A (ja) 2016-04-25
JP2016512216A5 true JP2016512216A5 (cg-RX-API-DMAC7.html) 2017-04-06

Family

ID=48771615

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015562236A Pending JP2016512216A (ja) 2013-03-15 2014-03-14 主要電荷アイソフォームに富んだ抗体組成物を含む新規な薬剤

Country Status (11)

Country Link
US (1) US20160046722A1 (cg-RX-API-DMAC7.html)
EP (1) EP2968533A1 (cg-RX-API-DMAC7.html)
JP (1) JP2016512216A (cg-RX-API-DMAC7.html)
KR (1) KR20150132522A (cg-RX-API-DMAC7.html)
CN (1) CN105163758B (cg-RX-API-DMAC7.html)
AU (1) AU2014230134A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015023209A8 (cg-RX-API-DMAC7.html)
CA (1) CA2907358A1 (cg-RX-API-DMAC7.html)
FR (1) FR3003171B1 (cg-RX-API-DMAC7.html)
MX (1) MX2015012812A (cg-RX-API-DMAC7.html)
WO (1) WO2014140322A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013004841A1 (en) * 2011-07-06 2013-01-10 Genmab A/S Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains
JP6934016B2 (ja) 2016-05-04 2021-09-08 デラヴァル ホルディング アーベー 乳頭カップのためのカートリッジ及び乳頭カップ
FR3053688B1 (fr) * 2016-07-06 2026-05-01 Lab Francais Du Fractionnement Mutants fc a activite fonctionnelle amelioree
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
EP3626265A1 (en) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
CN113614107A (zh) 2019-01-23 2021-11-05 Encefa公司 Cd31竞争剂及其用途
JP2022533245A (ja) * 2019-05-23 2022-07-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗体のドメイン特異的電荷変異体の特徴付け
CN114829407B (zh) * 2019-09-23 2024-06-21 南开大学 利用哺乳动物展示筛选FcγR特异性结合Fc
PL4401842T3 (pl) 2021-09-16 2025-11-24 Aboleris Pharma Domeny wiążące przeciwko ludzkiemu CD45RC i ich zastosowania
CN114236010A (zh) * 2021-12-18 2022-03-25 苏州莱奥生物技术有限公司 一种生物活性药物的药代动力学分析方法
CN115073548A (zh) * 2022-08-01 2022-09-20 上海蓝析生物技术有限公司 一种用于重组蛋白药物电荷异构体制备的缓冲体系

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0104865A3 (en) * 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
FR2844513B1 (fr) * 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
CA2832136C (en) * 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
KR100944575B1 (ko) * 2002-10-17 2010-02-25 젠맵 에이/에스 Cd20에 대한 인간 모노클로날 항체
US7355008B2 (en) * 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
FR2861078B1 (fr) * 2003-10-16 2007-09-21 Lab Francais Du Fractionnement NOUVELLES IgG3 UTILES POUR STIMULER LA PHAGOCYTOSE
EP2551282A3 (en) * 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
WO2013004841A1 (en) * 2011-07-06 2013-01-10 Genmab A/S Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains

Similar Documents

Publication Publication Date Title
ZA202308021B (en) Anti-ctla4 antibodies and methods of making and using the same
PH12019502561A1 (en) Novel monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4)
JOP20190248A1 (ar) بروتينات ربط مولد ضد trem2 واستخداماته
PE20221789A1 (es) Composiciones de proteina anti-vegf y metodos para producir la misma
MY205758A (en) Anti-nkg2a antibodies and uses thereof
MX2024013960A (es) Anticuerpos anti-ox40 y metodos de uso
MX2018006333A (es) Anticuerpos anti-receptor de muerte 5 (dr5) y metodos de uso de los mismos.
NZ734803A (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
MX2022001830A (es) Anticuerpos terapeuticos y sus usos.
RU2014147741A (ru) Модифицированные области антител и их применение
JOP20190002A1 (ar) أجسام مضادة (أنتي – بي دي – 1) وطريقة الإنتاج وطريقة استخدام كل منهم
PE20181451A1 (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
MX2021005193A (es) Anticuerpo que se une a fcrn para tratar enfermedades autoinmunes.
JP2017518258A5 (cg-RX-API-DMAC7.html)
BRPI0717363B8 (pt) imunoglobina humanizada que liga especificamente cd20, composição, vetor recombinante, métodos para obter uma célula hospedeira, de produção de uma imunoglobina que liga especificamente cd20, in viro para inibir o crescimento ou diferenciação de uma célula b humana normal e usos de imunoglobina e de uma quantidade efetiva de imunoglobina
MY206214A (en) Monoclonal antibodies that bind specifically to human trbv9
AR109683A1 (es) Anticuerpos contra el factor xi y sus usos
JP2016512216A (ja) 主要電荷アイソフォームに富んだ抗体組成物を含む新規な薬剤
WO2016164657A3 (en) Antibody therapeutics that bind cd123
MX2021003756A (es) Composiciones farmaceuticas que comprenden anticuerpos anti cumulo de diferenciacion 37 (cd37) biespecificos.
EA201891301A1 (ru) Антитела против dr5 и способы их применения
EA201992512A1 (ru) Антигенсвязывающие белки, связывающие trem2, и пути их применения
NZ780754A (en) Antigen-binding proteins that activate the leptin receptor
NZ780754B2 (en) Antigen-binding proteins that activate the leptin receptor
TH92866A (th) สารเหนี่ยวนำการตายของเซลล์